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Genetic modification of cell lines and primary cells is an expensive and cumbersome 
approach, often involving the use of viral vectors. Electroporation using square-wave 
generating devices, like Lonza’s Nucleofector, is a widely used option, but the costs 
associated with the acquisition of electroporation kits and the transient transgene 
expression might hamper the utility of this methodology. In the present work, we show 
that our in-house developed buffers, termed Chicabuffers, can be efficiently used to 
electroporate cell lines and primary cells from murine and human origin. Using the 
Nucleofector II device, we electroporated 14 different cell lines and also primary cells, like 
mesenchymal stem cells and cord blood CD34+, providing optimized protocols for each 
of them. Moreover, when combined with sleeping beauty-based transposon system, 
long-term transgene expression could be achieved in all types of cells tested. Transgene 
expression was stable and did not interfere with CD34+ differentiation to committed 
progenitors. We also show that these buffers can be used in CRISPR-mediated editing 
of PDCD1 gene locus in 293T and human peripheral blood mononuclear cells. The opti-
mized protocols reported in this study provide a suitable and cost-effective platform for 
the genetic modification of cells, facilitating the widespread adoption of this technology.
Keywords: electroporation, cell line, MSc, T lymphocyte, cD34, transposon, cRISpR, pD-1, gFp
InTRoDUcTIon
Cell lines are valuable tools for research development, constituting one of the pillars of experi-
mental biology. Their unlimited proliferative capacity, high degree of homogeneity, and relatively 
easy maintenance in culture allow the generation of large number of cells required for testing 
Abbreviations: CRISPR, clustered regularly interspaced short palindromic repeats; TALEN, transcription activator-like effec-
tor nucleases; PBMCs, peripheral blood mononuclear cells; MSCs, mesenchymal stem cells; GFP, green fluorescent protein; 
RFP, red fluorescent protein; 7-AAD, 7-amoniactinomycin D; ITR, inverted terminal repeats; SB, sleeping beauty transposase; 
dpi, days post inoculation; gRNA, guide RNA; NHEJ, non-homologous end joining; FITC, fluorescein isothiocyanate; HSC, 
human stem cell.
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numerous candidate drugs (Barretina et al., 2012), -omics profil-
ing (Nishizuka et al., 2003; Griffin and Shockcor, 2004; Blower 
et al., 2007), and signaling pathways studies (Park et al., 2010), 
to cite some examples. One of the areas that benefited the most 
with the use of cell lines was cancer research, with the deriva-
tion of several cell lines that can be used as models for different 
cancers. These cells are used to model disease in vitro and in vivo, 
providing information about oncogenesis-related pathways and 
insights into therapeutic strategies (Gillet et al., 2013). Moreover, 
cell lines are central players in the biotechnology industry, being 
used in the production of biopharmaceuticals like antibodies, 
hormones, and bioactive proteins in general (Kuystermans and 
Al-Rubeai, 2015).
The use of cell lines in basic research is often associated with 
genetic modification protocols, which allow overexpression 
and/or silencing of desired genes in a controllable fashion. 
Recently, the development of gene editing tools like TALENs 
and CRISPRs provided a more precise control of gene insertion 
or deletion, extending the possible genomic manipulations (Kim 
and Kim, 2014). Methods to deliver foreign genetic material 
(DNA or RNA) usually rely in nonviral or viral vectors, with 
the former being preferred because of increased biosafety, easier 
production, and faster translation. Electroporation is a nonviral 
method for gene transfer that is demonstrating encouraging 
results, being successfully used for the manufacture of antitumor 
lymphocytes (Ramanayake et al., 2015) and other applications 
(Kotnik et al., 2015), but the mechanism of DNA/RNA transfer is 
not fully understood (Satkauskas et al., 2012). Moreover, the use 
of electroporation is associated with extensive testing of electric 
parameters (pulse amplitude, volts) in order to optimize the 
protocol. Nonviral methods like liposomes and electroporation 
show varying efficiencies, with several cell lines and primary 
cells showing poor transfection rates and cell death (Wang et al., 
2012; Yin et al., 2014). In the case of liposomes, the transfection 
of non-adherent cell lines is rather inefficient, showing good 
results only for some adherent cells (Jordan and Wurm, 2004; 
Behr, 2012).
Using a square-wave pulse technology, Lonza’s Nucleofector 
electroporator was shown to be very efficient in several cell lines 
and primary human and murine cells, inducing high expression 
of the transgene and substantial viability. The pre-loaded elec-
troporation programs suited for each cell line simplify the experi-
mental setup, and the use of proprietary additives improves the 
transfection efficiency. However, the frequent use of Nucleofector 
electroporation kits implies in important costs for research 
labs, especially those in middle- to low-income countries. In a 
previous work, our group developed “in house” electroporation 
buffers (termed “Chicabuffers”) that had comparable efficiency 
with Lonza’s buffers for the transfection of the human T cell 
line Jurkat and primary T lymphocytes from mouse and human 
origin (Chicaybam et al., 2013). Electroporation strategies using 
Chicabuffers were recently successfully applied to colon cancer 
cell lines (de Souza et al., 2013) and human mesenchymal stem 
cells (MSC; unpublished data). In the present work, we extend the 
efficiency analysis of Chicabuffers and the description of optimal 
electroporation conditions in a panel of cell lines and primary 
cells that represent relevant models for cell biology studies and 
disease comprehension. We selected 14 cell lines of mouse and 
human origin and primary human cells [MSC, peripheral blood 
mononuclear cells (PBMCs), and cord blood CD34+ cells], show-
ing that these buffers yield high transfection efficiencies and are a 
viable option for genetic modification using the Nucleofector IIb 
electroporator. For cells in which the levels of transgene expres-
sion was low, we developed sleeping beauty (SB)-based transpo-
son plasmids engineered to confer drug resistance, allowing fast 
and efficient drug-based selection of cells representing fractions 
of the cell culture.
We selected cells lines representing models for hematopoietic 
neoplasias (HEL, K562, P815, Nalm-6, and Jurkat cell lines) and 
different solid tumor-derived cell lines (A-549, B16-F10, HeLa, 
MCF-7, MDA-MB-231). Some of the tested cells represent classi-
cal cellular models for ectopic gene expression (293T, NIH-3T3), 
cell signaling (Jurkat and 293T), growth factor dependence 
(BA/F-3), or simply relevant cells in terms of therapy and cell 
differentiation (MSCs, PBMCs and Cord Blood CD34+ cells). In 
addition, we show that the level of transfection achieved using 
Chicabuffers allows efficient genomic edition of the potentially 
clinical relevant PD1 locus in human cells, such as 293T and 
PBMCs, using the recently described CRISPR/Cas9 system (Jinek 
et al., 2012).
MATeRIAlS AnD MeThoDS
ethics Approval
The use of PBMCs and CD34+ cells from healthy donors was 
approved by an IRB (Brazilian National Cancer Institute—
INCA—Ethics Committee—protocol 153/13), and donors signed 
review board approved informed consents. MSCs were obtained 
from healthy donors submitted to surgery for hernia repair at 
the Clementino Fraga Filho University Hospital. The patients 
provided written informed consent, and the study was approved 
by the Hospital Research Ethics Committee.
plasmids and cloning
The pT3-GFP plasmid (Peng et  al., 2009) was kindly provided 
by Dr. Richard Morgan (Surgery Branch—NCI). The pT2-GFP 
and SB100X (Mátés et al., 2009) constructs were kindly provided 
by Dr. Sang Wang Han (UNIFESP, Brazil). For the creation of 
pT3-Neo-EF1a-GFP plasmid, GFP was excised from pT3-GFP 
by digestion with AgeI/NotI, and the neomycin resistance gene 
(NEO), which was synthesized by Genscript (Piscataway, NJ, 
USA), was inserted. The EF1a-GFP cassette was isolated from 
the plasmid pRRLsin.PPTs.EF1a.GFPpre (Bonamino et  al., 
2004) (provided by Dr. Didier Trono, EPFL, Switzerland) after 
digestion with ClaI/BstBI and inserted in pT3-NEO previously 
digested with ClaI. For CRISPR experiments, the plasmid 
encoding S. pyogenes Cas9 (WT) and a U6 promoter for guide 
RNA (gRNA) expression was acquired from Addgene (pX330; 
#42230). gRNA (CACCGGCCATCTCCCTGGCCCCCA) for 
programed cell death 1 (PDCD-1) was designed by Optimized 
CRISPR Design tool (http://crispr.mit.edu/) and cloned in pX330 
(Addgene) using BbsI restriction site. pRGS-CR (Kim et al., 2011) 
was provided by Dr. Amilcar Tanuri (Federal University of 
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Rio de Janeiro, Brazil), and PDCD1 target sequence cloned in 
EcoRI/BamHI sites, between a red fluorescent protein (RFP) and 
a GFP, resulting in an out-of-frame GFP. The GFP expression can 
be restored by CRISPR-mediated non-homologous end joining 
(NHEJ) repair. All plasmids were isolated using Qiamp Maxi prep 
kit from Qiagen (Germany) and quantified using a Nanodrop 
spectrophotometer. The new constructs described in this report 
are available at Addgene.
cell lines and primary cells
The origin and cell culture conditions for each cell line are 
described in Table S1 in Supplementary Material. The use of 
PBMCs from healthy donors was approved by an IRB (Brazilian 
National Cancer Institute—INCA—Ethics Committee), and 
donors signed review board approved informed consents. 
Within 24  h after blood collection, leukocytes were harvested 
by filtration and washed with phosphate buffered saline (PBS). 
A density gradient centrifugation using Ficoll-Hypaque®-1077 
was performed. Cells were centrifuged for 20 min at 890 g (slow 
acceleration/deceleration off), washed three times with PBS, and 
used for nucleofection. For CD34+ cells separation, mononuclear 
cells (MNCs) were isolated from umbilical cord blood after 
Ficoll density gradient using the same protocol above described. 
CD34+ cells were isolated from MNCs using CD34 MicroBead 
Kit (Miltenyi Biotech) following the manufacturer’s instructions. 
The utilization of CD34+ cells was also approved by INCA’s 
Ethics Committee.
Mesenchymal stem cells were isolated from abdominal 
subcutaneous adipose tissue fragments obtained from healthy 
donors submitted to surgery for hernia repair at the Clementino 
Fraga Filho University Hospital. The patients provided writ-
ten informed consent, and the study was approved by the 
Hospital Research Ethics Committee. Fragments were cut into 
small pieces and incubated with 1  mg/mL collagenase type II 
(Sigma-Aldrich, MO, USA) under permanent shaking at 37°C 
for 30 min. The cell suspension was centrifuged at 400 g, room 
temperature, for 10  min, and the pellet was resuspended on 
PBS, followed by filtration with 100-µm mesh strainers. Cells 
were plated to expand MSCs at 3 × 104 cells/cm2 density with 
low-glucose Dulbecco’s modified Eagle’s medium (DMEM 
Low-glucose, Gibco, CA, USA) supplemented with 10% fetal 
bovine serum (Gibco, CA, USA) and 100 U/ml penicillin and 
100 µg/mL streptomycin (Sigma-Aldrich, MO, USA). Cells were 
electroporated at passage 3.
electroporation
Generic cuvettes were used for all the electroporations (Mirus 
Biotech®, Madison, WI, USA cat.: MIR 50121). Cells were 
resuspended in 100  μl of the desired buffer, and 4  μg of the 
reporter plasmid (pT2-GFP transposon) were added. For 
long-term experiments, 1 μg of SB100× was added. The seven 
different buffers tested in this work are described in Table S2 
in Supplementary Material. Cells were transferred to a sterile 
0.2-cm cuvette and electroporated using the reported program 
(Table  1) of Lonza® Nucleofector® II electroporation system. 
After transfection, cells were gently resuspended in 1  mL of 
pre-warmed RPMI medium supplemented only with 2mM 
l-Glutamine and 20% FCS. All cells were seeded in 12-well 
plates and grown at 37°C and 5% CO2. The medium was replaced 
by complete RPMI medium the following day, and cells were 
maintained as described previously.
electroporation Score Determination
For non-adherent cell lines, viability determination was based 
on trypan blue exclusion and/or determination of the % of cells 
displaying viable cell FSC vs. SSC parameters by flow cytometry 
analysis on cells negative after 7AAD staining. For adherent 
cells, viability determination was calculated based on the % of 
the OD obtained in Crystal Violet staining assays at d +  1 or 
d + 3. Calculation was based on the formula % = 100 ×  [OD 
for control (non-electroporated) cell line/(OD for control (non-
electroporated) cell line + OD for electroporated cell line)]. The 
“electroporation score” was calculated based on cell viability 
(after normalization against the viability of non-transfected 
cells) and transgene expression on d +  1, and the score set to 
the formula “Viability (%)*Expression (%)/F.” A division factor 
(F =  50 for adherent cell lines and F =  100 for non-adherent 
cell lines) was used in the score formula to fit the results in the 
graph scale.
crystal Violet Staining
To assess viability of adherent cell lines, cells were plated in 
triplicate in 96-well microtiter plates immediately after elec-
troporation. Cell viability was evaluated after 24  h, and cell 
expansion was analyzed at day + 1 by crystal violet. The crystal 
violet incorporation assay was performed by fixing the cells with 
ethanol for 10 min, followed by staining them with 0.05% crystal 
violet in 20% ethanol for 10 min and solubilization with methanol 
as reported (Faget et  al., 2012). The plate was read on a spec-
trophotometer at 595 nm (SpectraMax 190, Molecular Devices, 
Sunnyvale, CA, USA).
In Vivo B16-F10 Tumor Model
B16F10 cells were electroporated with 4 µg of pT3-NEO-EF1a-
GFP and 1 µg of SB100× in buffer 1S, program P-020 of Lonza 
Nucleofactor II. As negative controls, we electroporated cells 
only with pT3-NEO-EF1a-GFP. Each condition was plated 
in a 6-well plate. After reaching 80% confluence, G418 (Life 
Technologies) antibiotic was added at 2,000 µg/mL. The medium 
was changed every 3 days and the antibiotic added. After selec-
tion with antibiotic or not, we injected 5 × 105 cells in the left 
flank of C57BL/6 mice. After 15 days, we excised the tumor and 
plated the cells in 25 cm2 culture flasks. After 24 h, the culture 
medium was changed to eliminate non-adherent cells. After 
3 days, the cells were recovered and analyzed by flow cytometry 
for GFP expression.
cD34+ Differentiation Assay
Electroporated CD34+ cells were assayed in two different 
concentrations, 5 × 102 and 2 × 103 cells/well. The cells were con-
centrated in 300 µL and then added in 1.1× concentrated 3 mL 
Methocult™ H4034 (Stem Cell Technologies Inc., Vancouver, 
BC, Canada), then seeded two wells of a six-well plates, 1.1 mL/
well. Cells were cultivated for 3 weeks at 37°C in a humidified 
TABle 1 | Summarized electroporation conditions for each cell line (based in Figure 2; d1 after electroporation).
cell line cell type program Recommended 
buffer
Viability 
(chicabuffer ± SD) 
(%)
Viability 
(lonza) 
(%)
gFp 
expression 
(chicabuffer) 
(%)
gFp 
expression 
(lonza) 
(%)
non-adherent
BA/F3 Mouse pro B cell X-001 2M 91.8 ± 2.7 79.00 55.05 ± 14.2 88.00
HEL Erythroleukemia; erythroblast cell X-005 1S 70.4 ± 17.1 39–66 79 ± 6.2 94.00
Jurkat Acute T cell leukemia, T lymphocyte; lymphoblastoid cells X-001 1SM 75.7 ± 6.8 90.00 69 ± 11.6 88.00
K562 Human chronic myelogenous leukemia; lymphoblastoid cells T016 1M 70.7 ± 13.8 88.00 64.1 ± 8 80–90
Nalm-6 Human B cell precursor leukemia C-005 3P 74.2 ± 11.8 87.00 40.6 ± 14.7 64.00
P815 Mouse mastocytoma; mast cells C-005 3P 70.2 ± 29.9 92.00 60.5 ± 16.6 62.00
Adherent
A549 Human lung carcinoma; epithelial cells X-001 3P 59.4 ± 27.3 81.00 63.5 ± 11.4 72.00
293T Human embryonal kidney; adherent fibroblastoid cells A-023 1SM 79.9 ± 24.7 90.00 38.6 ± 30.2 90.00
B16F10 Mouse skin melanoma P-020 2S 39.9 ± 17 91.00 49.3 ± 15.7 84.00
HeLa Human cervix carcinoma; epitheloid cells in monolayers I-013 1M 45.1 ± 16.5 85–90 66.4 ± 8.3 70.00
MCF7 Human breast adenocarcinoma; epithelial cells P-020 1M 68.4 ± 10.9 60.00 57 ± 23.3 77.00
MDA-
MB-231
Human breast adenocarcinoma; epithelial cells X-013 1SM 85.6 ± 15 77.00 48.5 ± 17.5 79.00
human 
MSCs
Human mesenchymal stem cell U-023 2S 58.5 ± 6.8 48.00 35 ± 16.6 80.00
NIH3T3 NIH Swiss mouse embryo; adherent fibroblastoid cells U-030 1SM 49.4 ± 30.4 87.00 52.5 ± 19.5 84.00
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atmosphere supplemented 5% CO2 in incubator 300/3000 Series 
(Revco, OH, USA). The colonies were identified and quantified 
using STEMvision™ (Stem Cell Technologies, Inc.) for the 
burst-forming units-erythroid, colony-forming units-erythroid, 
colony-forming units-granulocyte or macrophage or granulocyte-
macrophage, and colony-forming units-granulocyte/erythroid/
megakaryocyte/macrophage.
Flow cytometry
FACSCalibur® (BD Bioscience) was used to perform morphologic 
evaluation of viability (FSC vs. SSC) and GFP expression analysis. 
Cells were harvested the following days after transfection and 
resuspended in PBS at a concentration of 105 cells/500 μL. 7AAD 
staining (eBioscience cat. 00-6693) was performed immediately 
before FACS acquisition following manufacturer instructions. 
Data were analyzed using the FlowJo software (Tree Star). The 
hematopoietic progenitor CD34+ cells were evaluated for purity 
by staining with anti-CD34-PE (clone 581, BD Biosciences).
cRISpR-Mediated gene editing
HEK293FT and PBMCs were electroporated with pX330-
PDCD-1 (10  µg) and pRGS-CR-target (5  µg). Gene editions 
were evaluated by GFP+/RFP+ ratio after 24  h by flow 
cytometry. To characterize indels at PDCD1 locus, genomic 
DNA of gene edited cells was isolated by phenol–chloroform. 
Amplification of the target region was performed by PCR 
using the forward 5′-CCCCAGCAGAGACTTCTCAA and the 
reverse 5′-AGGACCGGCTCAGCTCAC primers. The PCR 
fragment was ligated in pCR2.1 vector (TA Cloning® Kit, Life 
Technologies), transformed in DH5α cells and single bacteria 
colonies has the plasmid DNA extracted and sequenced using 
the primers described above.
Short RnA and plasmid  
co-electroporation
After Ficoll gradient purification, PBMCs (107 cells) were 
electroporated with pRGS-CR-target (10  µg) and 10–50  pmol 
of FITC labeled RNA (Invitrogen) in Chicabuffer 3  P and 
U-014 Nucleofector IIb program. Cells were left resting in 
RPMI + 10%FCS for 24 h at 37°C and 5% CO2 and then evaluated 
by flow cytometry using ACCURI C6 (BD Bioscience).
Statistical Analysis
Data from electroporation experiments were analyzed by one-
way ANOVA followed by Tukey’s multiple comparison test using 
GraphPad Prism 6 software.
ReSUlTS
With the objective of determining the best-suited buffer for the 
electroporation of each cell line, cells were electroporated with 
seven different buffers and the viability and GFP expression were 
analyzed. Representative flow cytometry plots are depicted in 
Figure 1, showing 7AAD staining and GFP signal (gated in 7AAD 
negative cells) for a high electroporation score cell line (HEL) 
and FSC/SSC and GFP signal for a low score cell line (NIH3T3). 
7AAD staining was performed only in the non-adherent cells 
since they represent a mixture of viable and non-viable cells at 
day 1 post electroporation. Adherent cells were allowed to adhere 
overnight after electroporation, and non-adherent/dead cells 
FIgURe 1 | gFp expression after electroporation of representative cell lines. Representative plots of a high electroporation score cell line (HEL) and a low 
score cell line (NIH3T3). HEL was electroporated using buffer 2S and program X-005 and NIH3T3 using buffer 1SM and program U-030. For HEL, on day 1 after 
nucleofection, cells were stained with 7AAD (left column of graphs) and GFP expression was analyzed on 7AAD negative population (right column). For NIH3T3, 
viable cells were gated based on FSC/SSC and GFP was analyzed. Numbers depict the percentages of cells in each gate.
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were discarded before FACS analysis. As showed in Figure  2, 
the majority of cell lines showed high electroporation scores 
independent of the buffer, with exception of P815, which showed 
an overall low efficiency but demonstrated best performance with 
buffer 3P. Suspension cell lines showed the best results regarding 
GFP expression, in which values above 60% were recurrently 
obtained. One exception is Nalm-6, with a maximum of 40% of 
GFP-positive cells obtained using buffer 3P. Adherent cell lines 
showed GFP values slightly lower (30–65%), with Hela showing 
the best result with 66.4 ± 8.3% of GFP expression using buffer 
3P. Importantly, after 24 h of electroporation, the cells showed a 
good viability (Figure 2), allowing expansion and recovery from 
the nucleofection. Viability and GFP expression were followed 
for 10 days (suspension cell lines) or 7 days (adherent cell lines), 
with some cells retaining high levels of GFP (K562, HEL, B16F10) 
and others showing low expression of the marker after the expan-
sion (NIH3T3, Jurkat, P815) (Figures S1–14 in Supplementary 
Material). These results probably reflect the observed differences 
in nucleofection efficiency and proliferation rates among the 
studied cells. The electroporation protocol for each cell line is 
summarized in Table 1.
Stable gene expression is often required in the experimental 
setting, allowing the generation of subclones with overexpression 
or silencing of a gene of interest. The emergence of nonviral vec-
tors that allow the integration of transgenes, like the SB transpo-
son system, simplified the genetic modification of cells, requiring 
only the delivery of two plasmids to achieve stable expression 
(one encoding the transgene flanked by ITRs—inverted terminal 
repeats—and one encoding the transposase). In order to evaluate 
if Chicabuffers could be used with this system, 1 μg of SB100× 
(encoding a hyperactive version of the SB transposase) was 
electroporated with 4 μg of pT2-GFP and GFP expression was 
followed for 30  days. As showed in Figure  3, the addition of 
SB100× induced a higher percentage of GFP-positive cells after 
30  days of culture when compared with control cells, strongly 
suggesting that integration of the transgene has occurred. This 
effect was more pronounced in B16F10, HeLa, and MCF7 cell 
lines, with approximately 20% of GFP-positive cells at day 30. The 
other cell lines showed only a modest increase in GFP-positive 
cells at day 30, ranging from 2% (BA/F-3) to 12% (K562). The 
long-term levels of GFP expression did not correlate with GFP 
expression at early days after nucleofection, suggesting that the 
cell lines have different intrinsic susceptibilities to SB-induced 
transgene integration.
For fast and easy enrichment of GFP-positive cells, we con-
structed a bidirectional vector encoding GFP and G418 resistance 
in the backbone of pT3 transposon, named pT3-Neo-EF1a-GFP. 
Indeed, the expression level obtained after nucleofection was suf-
ficient to select G418-resistant clones after electroporation with 
this plasmid, as shown for NIH3T3 (Figure  4A) and B16F10 
(Figure  4B) cell lines. After G418 selection and withdrawal, 
GFP expression remained stable in NIH3T3 cells for 15  days 
(Figure S15 in Supplementary Material). Furthermore, when 
the modified B16F10 cells were injected in vivo and allowed to 
form subcutaneous tumors, the cells extracted from the tumor 
at d +  14 post inoculation (dpi) still expressed high levels of 
FIgURe 2 | electroporation score for cell lines. Cell lines were electroporated with pT2-GFP (4 μg) using each one of the seven buffers and the recommended 
program. Viability (blue bar), GFP expression (green bar), and electroporation score (red bar) were assessed 1 day after nucleofection (d + 1). Viability data were 
normalized with viability from non-transfected cells. Data are shown as mean ± SD from three experiments performed in duplicate and were further analyzed using 
one-way ANOVA with Tukey’s multiple comparisons test. Significant differences (p < 0.05) are depicted in the table next to each graph, with each color denoting one 
parameter.
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GFP, indicating that the transgenic cassette is integrated in the 
genome and has stable expression, with no signs of in vivo silenc-
ing of the transgene (Figure 4C; Figure S16 in Supplementary 
Material).
Variations of the pT3-Neo-EF1a-GFP construct were devel-
oped, such as the pT3-Neo plasmid, which confers resistance 
to G418 antibiotic and has restriction sites that allow cloning 
of a second expression cassette. This plasmid was validated in 
G418 resistance assays using B16F10 cells (data not shown). The 
map for this plasmid is shown in Figure S18 in Supplementary 
Material.
The use of primary cells derived from patients or healthy 
donors provides a more accurate model for in vitro and in vivo 
experiments, and these cells can also be used in cell therapy 
approaches to treat a large number of diseases. However, these 
applications often depend on genetic modification, which is usu-
ally hard to perform in these cells. To evaluate the performance 
of Chicabuffers in the gene transfer to these cells, we isolated 
adipose tissue derived MSCs and cord blood purified CD34+ 
hematopoietic stem cells and electroporated the cells with the 
plasmids pT2-GFP and SB100×. As shown in Figure  5A, the 
best electroporation score for MSC was obtained using buffer 
FIgURe 3 | long-term transgene expression in electroporated cell lines using sleeping beauty system. Cell lines were electroporated with pT2-GFP (4 μg) 
using the combination of buffer and program indicated on Table 1, with (white bar) or without (black bar) the addition of SB100× transposase (1 μg). GFP 
expression was analyzed until d + 30 for each cell line. Data are shown as mean ± SD from one single experiment performed in duplicate.
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FIgURe 4 | Transgene expression can be enriched by using g418 and is retained after in vivo growth. Using the programs and buffers indicated in 
Table 1, NIH3T3 (A) and B16F10 (B) cell lines were electroporated. G418 was added 2 days after nucleofection, and GFP expression was accompanied until 
d + 20 (NIH3T3) or d + 12 (B16F10). (c) 5 × 105 B16F10 cells submitted or not to selection with G418 were injected in the left flank of C57Bl/6 mice. Tumors were 
extracted 14 days post injection (dpi); cells were passed in vitro for 1 week and GFP expression analyzed by FACS.
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2S, with 57% of viable cells and 39% of GFP expression. When 
using SB100×, long-term expression of GFP using this buffer 
was seen in 12% of cells (Figure 5B). For CD34 + cells, around 
57% were GFP-positive 1 day after electroporation using buffer 
1SM and program U-008 (Figure 6A). These cells were plated in 
methylcellulose-based medium, allowing long-term assessment 
of GFP expression and differentiation potential. After 3 weeks, 
GFP+CD34+ cells were able to differentiate to erythroid, 
granulocytic, and myeloid lineages (Figure 6B), showing that the 
insertion of the transgene did not affect the stemness of the cells 
and that differentiated cells display high GFP expression (Figure 
S17 in Supplementary Mateiral).
The recent description of the CRISPR/Cas9 system as an effi-
cient tool to edit the genome of cells has clear implications for 
basic cell biology studies and gene therapy protocols (Doudna 
and Charpentier, 2014). To achieve efficient gene editing of 
target cells, Cas9 nuclease and the gRNA must be expressed in 
the cell, ideally in a transient fashion. To evaluate the efficiency 
of Chicabuffers in promoting Cas9-mediated genome editing, 
we designed a gRNA targeting exon 2 of PDCD1 gene, which 
encodes the inhibitory receptor PD-1, a relevant potential tar-
get for cancer cell-based immunotherapy (Hamid et al., 2013; 
Chicaybam and Bonamino, 2014). For the validation of gRNA, 
we used plasmid pRGS-CR-PDCD1, which has the PDCD1 
target sequence cloned between a RFP and a GFP, resulting in 
an out-of-frame GFP. In this system, GFP expression can be 
restored by CRISPR-mediated NHEJ repair (Kim et al., 2011), 
leading to restoration of the reading frame in nearly 1/3 of 
the editions. Co-electroporation of 293T cells with the report 
construct and the plasmid carrying CRISPR/Cas9/gRNA, but 
not CRISPR/Cas9 lacking the gRNA sequence, resulted in GFP 
expression in approximately 7% of the RFP+ cells (3% out 
of 42%), indicating that sequence-specific DNA editing was 
achieved (Figure  7A). A similar approach was performed in 
PBMCs and following electroporation, indels were verified by 
amplification of PDCD1 locus of the edited cells, which was 
subsequently cloned in pCR2.1 vector and analyzed by Sanger 
sequencing, evidencing cells containing indels of varying 
lengths in the PDCD1 locus (Figure  7B). The results of gene 
editing experiments in 293T and PBMCs are summarized in 
FIgURe 5 | Sleeping beauty-based gFp gene transfer to adipose 
tissue derived human mesenchymal stem cells (MScs). (A) MSCs were 
electroporated with each one of the seven buffers and the recommended 
program. Viability (blue bar), GFP expression (green bar), and electroporation 
score (red bar) were assessed 1 day after nucleofection (d + 1). (B) 
Long-term GFP expression was evaluated until d + 30 post nucleofection 
with (white bar) or without (black bar) the addition of SB100× transposase 
(1 μg per cuvette). Data are shown as mean ± SD from three experiments 
performed in duplicate and were further analyzed using one-way ANOVA with 
Tukey’s multiple comparisons test. Significant differences (p < 0.05) are 
depicted in the table next to each graph, with each color denoting one 
parameter.
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Figure 7C. The characterization of indels in PBMCs and 293T 
cells indicate that the use of our optimized electroporation 
protocol allowed efficient editing of PDCD1 locus in the tested 
samples. All the indels led to disruptions of the reading frame 
of the PD1 sequence (data not shown).
Multiple target editing is possible using CRISPR systems. Since 
multiple loci editing require multiple gRNA, we evaluated the 
possibility of co-electroporating PBMCs with a reporter plasmid 
and FITC labeled short RNAs. This setting could be used to co-
electroporate a plasmid encoding a reporter gene (or Cas9 nucle-
ase) and multiple short RNAs (such as gRNAs for editing several 
loci). Using the buffer 3P we were able to achieve high viability 
(Figure S19A in Supplementary Material) and up to 60.7% of 
cells expressing the short RNA when 50 pmol of the RNA were 
used (Figure S19B in Supplementary Material). Concentrations 
above 75 pmol of short RNA resulted in increased cell death and 
were not further used (data not show). From electroporated cells 
under the same condition, up to 14.8% co-expressed the reporter 
plasmid (encoding RFP) and the labeled short RNA (Figure S19C 
Supplementary Material). This setting clearly allows efficient co-
electroporation of plasmid DNA and short RNA, opening the 
possibility of combining siRNA and transgene expression or even 
multiple gRNAs and Cas9 expressing plasmids for gene editing.
DIScUSSIon
Genetic modification of cells is a cumbersome and expensive 
process, often involving the use of viral vectors to achieve high 
efficiency transgene expression. The use of electroporation 
for the genetic modification of cells is being adopted by many 
laboratories as it represents a fast and cheap option for transfer 
of plasmids and RNA. Moreover, this technique is also very effi-
cient, inducing transgene expression levels comparable to viral 
vectors in some cells (Bilal et al., 2015). Equipments capable of 
generating square-wave voltage pulses, like Lonza Nucleofector, 
are among the most efficient for mammalian cell electroporation 
(Mir, 2014). However, costs associated with the acquisition of 
nucleofection kits, especially if used in a routine basis, might 
hamper the use of this technology in some laboratories or impair 
large-scale experiments.
In a previous work, our group described seven in house 
buffers and tested the electroporation efficiency of Jurkat cells 
and primary lymphocytes using Nucleofector (Chicaybam et al., 
2013). The selected buffers induced high transgene expression 
and low toxicity, comparable to results obtained when Lonza’s 
kit were used. In this context, the present work comprises 
a practical guide for the electroporation of 14 cell lines and 
primary MSCs and HSCs, determining the best buffer (among 
seven options) to be used with Lonza Nucleofector II, a widely 
disseminated electroporation device. The electroporation score 
calculated for every cell line is a general guide for electropora-
tion efficiency comparison, and the buffer choice can be adapted 
to the need of the planned experiment (higher GFP expression 
or cell viability), allowing the researcher to experiment with 
different transgene expression levels. Chicabuffers showed to 
work for all the cells tested with most of the samples showing 
interchangeable results among the different buffers and only few 
exceptions where one of the buffers performed poorly or GFP 
expression was improved at the expense of cell viability, such 
as for buffer 3P in Jurkat cells. This illustrates that privileging 
GFP expression, for instance, can be detrimental to cell viability, 
opening room to further improvements in the electroporation 
protocol or buffer formulations. This results place Chicabuffers 
as a valuable tool for cheap and fast gene modification of basi-
cally every cell tested, with important potential applications in 
cell therapy and development and testing of synthetic circuits in 
mammalian cells. Although we focused in Lonza’s device, it is 
likely that a similar approach using these buffers in conjunction 
with electroporators that allow modification of electroporation 
conditions could achieve even better results by fine tuning 
parameters like pulse amplitude, voltage, and wave forms 
(Yarmush et al., 2014). Lonza’s buffers were already described to 
have good results when tested with alternative nucleofector IIb 
programs (Gresch et al., 2004), suggesting that there is still room 
for optimization of electroporation conditions, reinforcing the 
potential of testing Chicabuffers under different experimental 
settings.
Short-term viability and expression of GFP was very efficient 
for the majority of cell lines, and Chicabuffers performed equally 
well when compared to the results reported by Lonza, especially 
for non-adherent cell lines (Table 1 and Figure 2). Furthermore, 
FIgURe 6 | Sleeping beauty-based gFp gene transfer to human cord blood cD34+ cells. (A) GFP expression in CD34+ cells electroporated with plasmids 
pT2-GFP (4 μg) and SB100× (1 μg) using program U-008 and buffer 1SM. GFP expression was evaluated by FACS at d + 1 post nucleofection. (B) Electroporated 
cells (2 × 103 per well) were plated in methylcellulose media and allowed to differentiate for 3 weeks. Colonies were quantified for mock (left) and GFP electroporated 
(right) cells. GFP-positive colonies (black bars) were determined within total colonies identified. CFU-E, colony-forming unit-erythroid; BFU-E, burst-forming 
unit-erythroid; CFU-G/M/GM, colony-forming unit-granulocyte/monocyte/; CFU-GEMM, colony-forming unit-granulocyte–erythrocyte–monocyte–megakaryocyte. 
Data are shown as mean ± SD from two experiments.v
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our results are comparable to those reported in the literature 
for cell lines like K562 (Gresch et al., 2004) and primary MSCs 
(Aluigi et al., 2006), although direct comparison of the results 
must be taken carefully because different plasmids were used. 
By combining this strategy with the SB transposon system, the 
provided optimized protocols allowed long-term expression 
of transgenes in all the cells tested (Figure  3). In the case of 
viral vectors, especially retroviral and lentiviral vectors, there 
is a wide availability of constructs carrying selectable markers, 
fluorescent reporters, promoters for different finalities, and cas-
sette configurations, increasing the options of possible cellular 
manipulations (Szulc et  al., 2006; Weber et  al., 2008; Vargas 
et al., 2012). This is in sharp contrast to the SB system, which 
has a limited offer of transfer plasmids available. The new vectors 
developed and validated in the present report can improve flex-
ibility and increase the applicability of this system, promoting 
accessible and efficient transgene integration into different cell 
types. These plasmids showed high and stable levels of transgene 
expression, and the addition of antibiotic resistance allowed the 
selection of GFP-expressing clones in vitro. Long-term expres-
sion of the transgene can be potentially increased by the use 
of SB100× RNA, decreasing the toxicity of the electroporation 
process as reported (Peng et al., 2009), or by carefully titrating 
the transposase plasmid mass to avoid overproduction inhibi-
tion (Grabundzija et al., 2010). These vectors and others recently 
reported in the literature (Kowarz et al., 2015), in conjunction 
with Chicabuffers, could be potentially used in diverse experi-
mental gene therapy approaches, such as T cell immunotherapy 
(Singh et  al., 2015), MSCs (Martin et  al., 2014), and stem cell 
gene therapy protocols (Aiuti et  al., 2013), further facilitating 
the application of these technologies in basic, translational, and 
clinical studies.
Our results show the feasibility of this approach, enabling 
a stable transgene expression in CD34+ cells from cord blood 
samples, keeping GFP expression throughout hematopoietic dif-
ferentiation. It would be interesting to test this strategy in stem 
cell differentiation models other than the hematopoietic system 
such as the central nervous system (Sartore et al., 2011), includ-
ing models of in vivo differentiation. In addition, cells with clear 
therapeutic potential, such as T lymphocytes (Chicaybam et al., 
2013) and MSCs (this report) could be stably modified using a 
combination of Chicabuffer, SB, and electroporation.
Sleeping beauty-mediated modification of cells as described 
here proved to be stable in vitro and in vivo, with cells retaining 
transgene expression during tumor development in immuno-
competent mice. The GFP+ B16F10 cells not only retained GFP 
FIgURe 7 | electroporation of cRISpR/cas9 cassettes promotes gene editing of pBMcs and 293T cells. (A) 293T cells were electroporated (buffer 3P, 
program A-023) without plasmid (negative control), with pRGS-CR plasmid (without PDCD1 target sequence; mock), or with pRGS-CR-PDCD1. GFP and red 
fluorescent protein expression was analyzed 24 h later. Numbers depict the percentage of cells inside each gate. (B) Representative image showing indels obtained 
in PDCD1 gene after electroporation of PBMCs with plasmid px330 (Cas9/gRNA). The indels are represented by lower case characters; numbers inside parenthesis 
depict substitutions (~) and numbers outside parenthesis depict additions (+) or deletions (−). Exons are not draw into scale. (c) Summarized results obtained for 
293T cells and PBMCs, showing the number of colonies sequenced and the percentage of indels detected. Two experiments were done for each cell.
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expression level, but also kept a constant ratio of GFP+/GFP− cells 
throughout the 15-day period of in vivo tumor development. This 
result suggests that no gene silencing occurs for the SB transgenic 
cassette, supporting in vivo utilization of this tool, as described 
elsewhere (Belur et al., 2003; Hausl et al., 2010).
Furthermore, we showed efficient CRISPR-mediated genome 
editing of PDCD1 gene in 293T and human PBMCs electroporated 
using Chicabuffers. Designing a single plasmid encoding Cas9+ 
gRNA is simpler than constructing zinc finger nuclease (Beane 
et  al., 2015) or TALEN (Berdien et  al., 2014)-based cassettes. 
The single plasmid approach for PBMC edition is also simpler to 
assemble than the recently reported Cas9+ gRNA ribonucleopro-
teins (Schumann et al., 2015), showing that our extremely simple 
protocol can be used to edit cell genomes. The gRNA used for 
PDCD1 locus edition in our report targets exon 2, in contrast 
to exon 1 editions promoted by Schumann et al. (2015), show-
ing that different gRNAs can be used to efficiently disrupt the 
PDCD1 gene sequence. The levels of gene editing obtained with 
our approach allow similar downstream applications in primary 
lymphocytes as those proposed by the above mentioned reports, 
but with a reduced effort to design the gene editing tool (plasmid 
bases CRISPR system vs. TALEN or ZFN) or the electroporation 
reagents (plasmid vs. RNA + protein). Furthermore, the protocol 
described for the co-electroporation of short RNAs and plasmids 
carrying GFP+ Cas9 can be exploited for multiple loci editing 
in PBMCs, opening the possibility of targeting simultaneously 
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several genes of interest. These results suggest that Chicabuffers 
can be used for CRISPR genome editing in different cell lines and 
primary cells, including large-scale screening of different gRNAs.
In summary, our study describes general guidelines for the 
efficient electroporation of primary mammalian cells and several 
cell lines. For cell lines not described in this study, Chicabuffers 
represent a good starting point for the optimization of elec-
troporation protocol and facilitate the genetic modification of 
cell lines that are not frequently used. Furthermore, our data 
validate a series of flexible SB-based plasmids for the integration 
of transgenes and downstream selection of gene-modified cells. 
The combination of transposon, Chicabuffers, and electropora-
tion, as described here, represents a straightforward approach for 
transient gene expression and permanent gene modification of 
cell lines and human primary cells.
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